NCT07037563Recruiting
Developing an AI Pharmacy Chatbot for the Population of Hong Kong
Source: ClinicalTrials.gov · Last updated 25 Jun 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The primary objective of this study is to is to develop a conversational AI service (chatbot) in Hong Kong to assist patients and caregivers with inquires related to Hospital Authority (HA)-prescribed medications, and to evaluate its effectiveness in answering medication-related questions. The main questions it aims to answer are: 1. How satisfied are the patients and caregivers with this pharmacy chatbot? 2. How will the pharmacy chatbot impact eligible patients or caregivers on their (or the patient they are caring for) medication adherence, knowledge, and the consultation time with HA pharmacists? There will be an intervention group and a control group: 1. The intervention group will be invited to use the AI Pharmacy Chatbot online for 7 days through WhatsApp, a commonly used social media platform in Hong Kong. They can inquire about their medications prescribed under HA and get instant, validated answers from the chatbot. 2. The control group will not use the chatbot during the intervention period. To evaluate the chatbot's usability, researchers will measure patient satisfaction through usability questionnaires issued to the intervention group after their intervention period. Differences in medication adherence, medication knowledge, and HA pharmacist consultation time will also be measured between the intervention and control groups after the intervention period, to determine the chatbot's impact.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 280 (estimated)
- First submitted
- 17 Jun 2025
- Start date
- 1 Jun 2025
- Primary completion date
- 31 Oct 2026
- Lead sponsor
- The University of Hong Kong
- Diseases
- High blood pressure
- NCT number
- NCT07037563
What you commit to
- Study type: Interventional
- Planned participants: 280
- From 1 Jun 2025 to the primary completion date, 31 Oct 2026
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- There is no exclusion criterion, but they should meet the inclusion criteria above.
Who the study is looking for
- Patients aged 18 years or older diagnosed with either hyperglycaemia, hypertension, or hyperlipidaemia, and currently receiving medication prescribed by the Hospital Authority in Hong Kong.
- Caregivers aged 18 years or older for patients described above.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The University of Hong Kong Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
| Laboratory of Data Discovery for Health Coordinator of this site? Confirm its status | Hong Kong | Hong Kong SAR China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.